🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. B013

    BRIGHT MINDS BIOSCIENCES INC.

    Platinum-resistant Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  2. BAX69 + infusional 5-FU/LV

    Takeda

    Metastatic Colorectal Cancer

    phase 2 mab terminated

    1 trial

  3. BAX69 Single-Route Arm

    Takeda

    Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites

    phase 2 mab terminated

    1 trial

  4. BAY 1841788, DEGARELIX , LEUPRORELIN , TRIPTORELIN , GOSERELIN , TRIPTORELIN PAMOATE

    Ningbo Cancer Hospital

    Hormone Naive Prostate Cancer

    phase 2 small molecule active

    1 trial

  5. BC1 cell line

    BriaCell Therapeutics

    Breast Cancer

    phase 2 mab active

    1 trial

  6. BCG (50mg/instillation) + N-803 (400 μg/instillation)

    Immunitybio Ireland Limited

    Non-muscle Invasive Bladder Cancer

    phase 2 mab active

    1 trial

  7. BCG-MEDAC, poudre et solvant pour suspension intravésicale, PD1IL2v iMAb

    Hoffmann-La Roche

    BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)

    phase 2 small molecule active

    1 trial

  8. BDC-1001

    Bolt Biotherapeutics

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  9. BDC-1001, PERTUZUMAB

    Bolt Biotherapeutics

    HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER

    phase 2 small molecule active

    1 trial

  10. BDC-4182

    Bolt Biotherapeutics

    Gastric Cancer Adenocarcinoma Metastatic

    phase 2 small molecule active

    1 trial

  11. BENDAFOLIN 10 mg/ml Injektionslösung, Gemcitabin HEXAL® 40 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Benda-5 FU 50 mg/ml Injektionslösung, Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, AZD0901

    AstraZeneca AB

    Gastric Cancer, Gastroesophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  12. BEVACIZUMAB, DC-VACCINE_IRSTIRCCS, Lonsurf 20 mg/8.19 mg film-coated tablets, VEGZELMA 25 mg/mL concentrate for solution for infusion, VEGZELMA 25 mg/mL concentrate for solution for infusion, Lonsurf 15 mg/6.14 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BEVACIZUMAB

    Istituto Gentili S.r.l.

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  13. BEVACIZUMAB, IRINOTECAN, FOLINIC ACID, Telisotuzumab adizutecan, FLUOROURACIL

    AbbVie Deutschland GmbH & Co. KG

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  14. BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, GEMCITABINE, NIVOLUMAB, PEMETREXED, PACLITAXEL, CARBOPLATIN

    CERO THERAPEUTICS HOLDINGS, INC.

    Non Small Cell Lung Cancer, Interstitial Lung Disease

    phase 2 small molecule active

    1 trial

  15. BGB-A317

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule completed

    1 trial

  16. BL-B01D1

    Sichuan Baili Pharmaceutical Co.,

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. BL-B01D1

    Sichuan Baili Pharmaceutical Co.,

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  18. BLEOMYCIN

    Fondazione Telethon ETS

    colorectal cancer

    phase 2 small molecule active

    1 trial

  19. BLEOMYCIN, CISPLATIN

    Fondazione Telethon ETS

    patients with newly diagnosed or recurrent high-grade or initially invasive precancerous squamous lesions of the vulva and non-invasive vulvar Paget's disease

    phase 2 small molecule active

    1 trial

  20. BLEOPRIM 15 mg polvere per soluzione iniettabile, Fluorouracil 50 mg/ml Solution for Injection or Infusion, LEDERFOLIN 25 mg Polvere per soluzione iniettabile per uso endovenoso, CAMPTO 20 mg/mL concentrate for solution for infusion, Oxaliplatin 5 mg/ml Concentrate for Solution for infusion

    Fondazione Telethon ETS

    Locally Advanced Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  21. BMS-986525, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. BNT116

    Regeneron UK Limited

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  23. BNT116, LIBTAYO 350 mg concentrate for solution for infusion.

    Lacuna Pharma Pty Ltd

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. BNT327, BNT314, BNT327 1-15

    BioNTech SE

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources